Get started
Author

Jan G. C. E. Cosaert

Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
2009 · Eric Van Cutsem, Walter L. Vervenne, et al. · Journal of Clinical Oncology · 650
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
2016 · William D Tap, Robin L Jones, et al. · The Lancet · 584
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
2024 · Benjamin Besse, Elvire Pons-Tostivint, et al. · Nature Medicine · 131
PDF
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer
2021 · Thomas Powles, Danielle Carroll, et al. · Nature Medicine · 119
PDF
A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors
2017 · Anthony W. Tolcher, Jordan D. Berlin, et al. · Cancer Chemotherapy and Pharmacology · 105
Platinum drugs in the treatment of non-small-cell lung cancer
2002 · J Cosaert, E Quoix · British Journal of Cancer · 102
PDF
Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy
2015 · William J. Gradishar, Denise A. Yardley, et al. · Clinical Cancer Research · 73
A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer
2008 · W. Vervenne, J. Bennouna, et al. · Journal of Clinical Oncology · 50
Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours
2023 · Melissa L. Johnson, Judy S. Wang, et al. · British Journal of Cancer · 38
PDF
An adaptive, biomarker directed platform study in metastatic urothelial cancer (BISCAY) with durvalumab in combination with targeted therapies
2019 · T. Powles, A. Balar, et al. · Annals of Oncology · 32
An Open-Label, Dose–Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma
2016 · Danny N. Khalil, Michael A. Postow, et al. · Clinical Cancer Research · 31
Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma
2008 · Bernard Escudier, Jan Cosaert, et al. · Expert Review of Anticancer Therapy · 27
KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer
2025 · Ana Galan-Cobo, Natalie I. Vokes, et al. · Cancer Cell · 26
Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA Study
2009 · C. Verslype, W. Vervenne, et al. · Journal of Clinical Oncology · 25
Blockade of Insulin-Like Growth Factor Type-1 Receptor with Cixutumumab (IMC-A12): A Novel Approach to Treatment for Multiple Cancers
2011 · Eric K. Rowinsky, Jonathan D. Schwartz, et al. · Current Drug Targets · 24
COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer
2024 · Neil H. Segal, Jeanne Tie, et al. · British Journal of Cancer · 22
OA07.08 HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Phase II Platform Study in Patients with NSCLC, who Progressed on Anti-PD(L)1 Therapy
2021 · B. Besse, M. Awad, et al. · Journal of Thoracic Oncology · 22
Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors
2017 · Patricia M. LoRusso, Mrinal Gounder, et al. · Investigational New Drugs · 22
An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer
2016 · Silvia Novello, Giorgio Scagliotti, et al. · Journal of Thoracic Oncology · 21
PDF
French Multicentre Trial Comparing CasodexdC1176,334) Monotherapy with Castration plus Nilutamide in Metastatic Prostate Cancer: A Preliminary Report
1994 · C. Châtelain, V. Rousseau, et al. · European Urology · 21
Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma
2018 · Renata Ferrarotto, William N. William, et al. · Oral Oncology · 20
Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy.
2011 · B. Grana, H. A. Burris, et al. · Journal of Clinical Oncology · 20
A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (PDGFRα) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS).
2015 · William D. Tap, Robin L Jones, et al. · Journal of Clinical Oncology · 18
Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors
2015 · C. S. Higano, J. Berlin, et al. · Investigational New Drugs · 14
Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC
2017 · David E. Gerber, Paul Swanson, et al. · Lung Cancer · 13
Works count: 74
Citation count: 2,318
H-index: 20
I10-index: 27
Year
Topic
Type